Femoxetine

Femoxetine

Systematic (IUPAC) name
(3R,4S)-3-[(4-methoxyphenoxy)methyl]-1-methyl-4-phenyl-piperidine
Clinical data
Legal status	Uncontrolled
Routes of administration	Oral
Pharmacokinetic data
Biological half-life	7-27 hours
Identifiers
CAS Number	59859-58-4
ATC code	none
PubChem	CID: 3012003
ChemSpider	2280941 Y
UNII	8Y719ZLX8C Y
ChEMBL	CHEMBL94739 Y
Chemical data
Formula	C20H25NO2
Molecular mass	311.42 g/mol
SMILES O(c1ccc(OC)cc1)C[C@@H]3[C@@H](c2ccccc2)CCN(C)C3
InChI InChI=1S/C20H25NO2/c1-21-13-12-20(16-6-4-3-5-7-16)17(14-21)15-23-19-10-8-18(22-2)9-11-19/h3-11,17,20H,12-15H2,1-2H3/t17-,20-/m1/s1 Y Key:OJSFTALXCYKKFQ-YLJYHZDGSA-N Y
(verify)

Femoxetine (INN) (tentative brand name Malexil; developmental code name FG-4963) is a drug related to paroxetine that was being developed as an antidepressant by Danish pharmaceutical company Ferrosan in 1975 before acquisition by Novo Nordisk. It acts as a selective serotonin reuptake inhibitor (SSRI). Development was halted to focus attention on paroxetine instead, given femoxetine's inability to be administered as a daily pill.

Both femoxetine and paroxetine were invented in the 1970s by Jorgen Buus-Lassen (Jørgen Anders Christensen name on the patents though). After Ferrosan's acquisition, femoxetine died from neglect.

See also

• Alaproclate
• Indalpine
• Zimelidine